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Abstract
Background: Synovial sarcoma is a malignant neoplasm of soft tissues. It occurs mainly in the extremities and is
closely related to tendons, tendon sheaths, and bursal structures. Primary synovial sarcoma of the pleura and lungs
is extremely rare.
Case presentation: We present the case of a 62-year-old man with a large synovial sarcoma of the left pleura.
He presented with general fatigue and severe dyspnea. Chest computed tomography (CT) revealed a 20-cm
tumor in the left thoracic cavity. We first diagnosed the tumor as a sarcomatoid mesothelioma based on
CT-guided needle biopsy. We speculated that his severe dyspnea was because of ventilation-perfusion
mismatch due to the left pulmonary collapse. Furthermore, we thought that there was a discrepancy between the
CT findings and the pathological findings from the biopsy specimen. We performed pleuropneumonectomy through
an anterior approach with median sternotomy and 5th-intercostal thoracotomy. The resected specimen contained a
22-cm pleural tumor with parenchymatous hemorrhage. We diagnosed the tumor as monophasic synovial sarcoma
based on its morphologic and immunohistochemical features. We suspected there was microscopic residual tumor in
the left diaphragm and therefore performed radiation therapy. After radiotherapy, he received adjuvant chemotherapy
with ifosfamide and Adriamycin. One year after surgery, the patient is alive with no signs of tumor recurrence.
Conclusions: We report a case of a large synovial sarcoma of the pleura in a patient with severe dyspnea. He was
treated with pleuropneumonectomy, radiotherapy, and adjuvant chemotherapy. Although the best treatment for this
rare condition has not been defined, we thought that tumor resection and adjuvant therapy were appropriate to
control the disease in this case.
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Background
Primary synovial sarcoma of the pleura is extremely rare.
Optimal treatment for synovial sarcoma of the pleural
has not been defined. We describe a case of large syn-
ovial sarcoma of the pleura, which was resected via
pleuropneumonectomy.
Case presentation
A 62-year-old man presented with general fatigue and
severe dyspnea. He was an ex-smoker. He did not have a
history of exposure to asbestos. Physical examination
revealed oxygen saturation of 90% (room air) and
decreased left vesicular sounds. Arterial blood gas ana-
lysis indicated the following results: pH 7.4752, pO2
73.9 mmHg, and pCO2 24.8 mmHg (O2 2 L/min). Spir-
ometry was not performed because of severe dyspnea.
Chest radiography showed a large pleural effusion in the
left thoracic cavity (Fig. 1a). On chest computed tomog-
raphy (CT), a 20-cm tumor in the left thoracic cavity
was visible (Fig. 1b). Removal of pleural fluid was
performed, and the cytology of the pleural fluid was
negative for malignancy. CT-guided needle biopsy was
performed. The pathological findings showed a prolif-
eration of atypical short spindle or oval cells with
hyperchromatic nuclei and eosinophilic cytoplasm.
Immunohistochemically, the tumor cells were positive
for D2-40, BCL-2, CD99, and p53; they were negative
for TTF-1, WT1, calretinin, cytokeratin (CK)5/6, CK7,
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CK20, HBME-1, CEA, and CD34. The biopsy speci-
men was diagnosed as a sarcomatoid mesothelioma.
One month after admission, CT showed that the
tumor had rapidly grown in size and the pleural effu-
sion in the right cavity was slightly increased (Fig. 1c).
We thought that the pleural effusion in the right
cavity was due to inflammation. We did not perform
thoracentesis for the right pleural effusion. We specu-
lated that his severe dyspnea was because of
ventilation-perfusion mismatch caused by the left pul-
monary collapse. Furthermore, we thought that there
was a discrepancy between CT findings and patho-
logical findings from the biopsy specimen. We
planned a pleuropneumonectomy to improve of his
performance status. The tumor was too large to be
removed using the usual posterolateral incision;
hence, we performed an anterior approach with
median sternotomy and 5th-intercostal thoracotomy.
Because the adhesion between the tumor and dia-
phragm was tight, it was difficult to perform en bloc
resection of the tumor. We performed partial resec-
tion of the diaphragm which was adhered with tumor
tightly. Although the tumor was completely resected
macroscopically, we suspected there was microscopic
residual tumor in the left diaphragm. The surgical op-
erating time was 306 min, and total blood loss was
3180 cc. His postoperative course was uneventful, and
he was discharged on postoperative day 21. His per-
formance status had improved from 3 to 1.
The resected specimen showed a 22-cm pleural
tumor with parenchymatous hemorrhage (Fig. 2a).
Pathological findings showed a proliferation of atypical
short spindle or oval cells with hyperchromatic nuclei
and eosinophilic cytoplasm arranged in fascicles,
whorls, or in a herringbone pattern with necrotic foci,
associated with gaping thin-walled blood vessels dis-
playing a hemangiopericytoma-like appearance (Fig. 2b).
Mitotic figures were readily encountered.
Immunohistochemically, the tumor cells were positive
for epithelial membrane antigen (EMA), D2-40, BCL-2,
CD99, and p53. They were negative for TTF-1, WT1,
calretinin, cytokeratin (CK)5/6, CK7, CK20, HBME-1,
CEA, and CD34. Because the tumor cells were positive
for CD99 and BCL-2, which are usually negative in a
case of malignant mesothelioma, malignant sarcomatoid
mesothelioma seemed to be less of a possibility. In a
molecular assay using the formalin-fixed, paraffin-
embedded tumor tissue, no SS18-SSX fusion gene
transcript, a characteristic of synovial sarcoma, was iden-
tified despite the detection of messages of housekeeping
genes (PGK and PBGD) used as internal controls. In
addition, the fluorescence in situ hybridization (FISH)
analysis using an SS18 break apart probe failed to iden-
tify a convincing gene rearrangement. However, synovial
Fig. 1 Preoperative imaging studies. The chest radiogram shows a
large pleural effusion in the left thoracic cavity and a mediastinum
shift to the right (a). Contrast-enhanced computed tomography (CT)
on admission shows a 20-cm tumor and pleural effusion in the left
thoracic cavity (b). Contrast-enhanced CT a month after admission
shows that the tumor has rapidly grown and the right pleural
effusion has increased since admission (c)
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sarcoma cannot be ruled out because it can have a
minor fusion gene variant (SS1821-SSX), which we did
not test for.
We diagnosed the tumor as a monophasic synovial
sarcoma based on its morphologic and immunohisto-
chemical features. Because we suspected that there was
residual microscopic tumor, 50 Gy of radiation was
delivered to the diaphragm. Thereafter, adjuvant chemo-
therapy with ifosfamide and Adriamycin, which are
administered for cases of soft tissue sarcoma in the
extremities, was administered. Currently, he is alive and
doing well, without evidence of recurrent disease
12 months after the surgery.
Synovial sarcoma is a malignant neoplasm of soft
tissues. It occurs mainly in the extremities and is closely
related to tendons, tendon sheaths, and bursal struc-
tures. Primary synovial sarcoma of the pleura and lungs
is extremely rare [1–3]. The common histological sub-
types of synovial sarcoma are biphasic, monophasic spin-
dle cell or fibrous, monophasic epithelial, and poorly
differentiated subtypes [4]. The biphasic type is easily di-
agnosed based on the presence of both epithelial and
spindle cell components. The monophasic type is diffi-
cult to diagnose, because it has a uniform spindle cell
pattern, which is similar to other malignant spindle cell
neoplasms [5].
In our case, at first, we diagnosed the tumor as a
sarcomatoid mesothelioma. In the biopsy specimen, we
did not find a proliferation of atypical cells with a
hemangiopericytoma-like appearance, which was found
in the resected specimen. Immunohistochemical findings
play an important role in the differential diagnosis of
synovial sarcoma. Synovial sarcoma is almost always
positive for cytokeratins and EMA. Synovial sarcoma
lacks staining for neural (S100) and smooth muscle
(desmin and smooth muscle actin) markers [6]. The
chromosomal translocation t(X;18)(p11.2;q11.2) has
been found in more than 90% of synovial sarcomas,
regardless of histologic subtype [7]. This translocation
results in the fusion of the SYT gene on chromosome 18
to either the SSX1 or SSX2 gene on chromosome X [8].
In our case, no SS18-SSX fusion gene transcript was
identified. In addition, the FISH analysis using an SS18
break apart probe failed to identify a convincing gene
rearrangement. However, the tumor was diagnosed as
monophasic synovial sarcoma based on its morphologic
and immunohistochemical features.
Optimal treatment for synovial sarcoma of pleura has
not been defined. Multimodal therapy involving surgery,
chemotherapy, and radiotherapy has been used. Radical
resection with an adequately wide margin is the standard
operation, similar to that used for other soft tissue sarco-
mas [9]. Adjuvant radiotherapy is usually recommended
after incomplete resection. Adjuvant chemotherapy
using doxorubicin ± ifosfamide is significantly beneficial
in terms of 5-year disease-free and overall survival in
cases of soft tissue sarcoma [10]. In a phase II study of
perioperative chemotherapy with ifosfamide and doxo-
rubicin for high-grade soft tissue sarcomas in the ex-
tremities including synovial sarcoma, the 2- and 5-year
progression-free survival rates were found to be 75.7%
(95% CI, 63.9–84.1%) and 63.8% (95% CI, 51.3–73.9%),
respectively, and the 5-year overall survival was 82.6%
(95% CI, 71.3–89.7%) [11].
In our case, microscopically residual tumor in the left
diaphragm was suspected, and therefore, radiation ther-
apy was performed. After radiotherapy, adjuvant chemo-
therapy with ifosfamide and Adriamycin, which are
administered for soft tissue sarcoma in the extremities,
Fig. 2 Pathological examination. The cut surface of the resected
specimens shows a pleural tumor with parenchymatous hemorrhage
(a). Microscopic examination (hematoxylin-eosin staining) shows a
proliferation of atypical short spindle or oval cells with hyperchromatic
nuclei and eosinophilic cytoplasm arranged in fascicles, whorls, or in
a herringbone pattern with necrotic foci, associated with gaping thin-
walled blood vessels displaying a hemangiopericytoma-like
appearance (b)
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was administered. Galetta reported 15 cases of pri-
mary thoracic synovial sarcoma. Factors that adversely
affect survival include a tumor dimension of greater
than 10 cm, incomplete resection, and no adjuvant
therapy [12].
In our case, we initially diagnosed a sarcomatoid
mesothelioma based on CT-guided needle biopsy. The
preoperative TNM classification for malignant pleural
mesothelioma according to the International Mesotheli-
oma Interest Group was stage II (T2N0M0). The
National Comprehensive Cancer Network Guidelines for
malignant pleural mesothelioma recommend chemo-
therapy for sarcomatoid mesothelioma. Indications for
surgery in our case were controversial. In our case, the
large tumor was causing ventilation-perfusion mismatch
through the left pulmonary collapse. Therefore, the
patient experienced severe dyspnea. The tumor rapidly
grew over a 1-month period. The patient was relatively
young and had no comorbidities. We thought that resec-
tion of the large tumor would improve his condition.
Thus, this was a rescue surgical intervention case for
severe dyspnea and a critical status. Furthermore, we
thought that there was a discrepancy between the CT
findings and the pathological findings of the biopsy
specimen, which was an additional reason for perform-
ing surgical resection. After surgery, the patient’s re-
spiratory condition improved and his performance status
improved from 3 to 1. Hara reported a similar case with
very rapid progression of the tumor, and the patient died
only 2 months after first presentation [13]. We thought
that tumor resection for control of the disease was
appropriate.
Conclusions
We report a case of a large synovial sarcoma of the
pleura in a patient with severe dyspnea, who was treated
with pleuropneumonectomy, radiotherapy, and adjuvant
chemotherapy. Although the best treatment has not
been defined, we thought that tumor resection and adju-
vant therapy were appropriate for control of the disease
in this case.
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